Characterization of the tachykinin NK2 receptor in the human bronchus: influence of amastatin-sensitive metabolic pathways.
1. The aim of this study was to characterize the tachykinin NK2 receptor subtype mediating the spasmogenic response in the human isolated bronchus. The motor response to neurokinin A (NKA) and the selective NK2 agonist [beta Ala8]NKA(4-10), as well as the antagonistic effects of cyclic (L659,877) and linear (MEN 10376) peptide NK2 antagonists were assessed in the presence or absence of amastatin (an inhibitor of aminopeptidases A and M). 2. NKA was more potent than [beta Ala8]NKA(4-10) in eliciting bronchoconstriction (pD2 being 7,43 and 6,87 respectively). In the presence of amastatin (1 microM), the estimated affinity of [beta Ala8]NKA(4-10), but not that of NKA, was significantly increased to yield a pD2 of 7,44. 3. L659,877 and MEN 10376 inhibited [beta Ala8]NKA(4-10)-induced contraction with similar affinities; pA2 values were 5.7 +/- 0.22 and 6.3 +/- 0.32, respectively. Amastatin (1 microM) increased the potency of MEN 10376 to 7.28 +/- 0.46, whereas that of L659,877 was unaffected. 4. In the presence of amastatin the pseudopeptide MDL 28,564 behaved as a partial agonist. 5. We conclude that the NK2 receptor subtype present in the human bronchus has properties similar to those described for the circular muscle of the human colon and thus may be classified as a 'NK2A' subtype. We show that the apparent potency of peptides, bearing N-terminal acidic residues, is influenced by an amastatin-sensitive peptidase, possibly aminopeptidase A.
Astolfi
M
M
Pharmacology Department, Menarini Ricerche Sud, Pomezia, Rome, Italy.
Treggiari
S
S
Giachetti
A
A
Meini
S
S
Maggi
C A
CA
Manzini
S
S
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects / Q000378:metabolism*; D001986:Bronchial Spasm / Q000139:chemically induced / Q000503:physiopathology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008969:Molecular Sequence Data; D015288:Neurokinin A / Q000031:analogs & derivatives / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides; D010456:Peptides, Cyclic / Q000494:pharmacology; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000378:metabolism; D015320:Tachykinins / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D010446:Peptide Fragments; D010455:Peptides; D010456:Peptides, Cyclic; D018041:Receptors, Neurokinin-2; D015320:Tachykinins; C064218:neurokinin A (4-10), beta-Ala(8)-; C073361:cyclo(Gln-Trp-Phe-Gly-Leu-Met); C066015:MDL 28564; C069192:neurokinin A(4-10), Tyr(5)-Trp(6,8,9)-Lys(10)-; C016977:amastatin; D015288:Neurokinin A